Methotrexate plasma pharmacokinetics: importance of assay method

Area of Science:

• Pediatric Oncology
• Clinical Pharmacology
• Analytical Chemistry

Background:

• Intravenous methotrexate (MTX) is a cornerstone in pediatric cancer treatment.
• Accurate pharmacokinetic monitoring is crucial for optimizing MTX dosage and leucovorin rescue.
• Current assay methods for MTX plasma concentrations may influence therapeutic outcomes.

Purpose of the Study:

• To evaluate the impact of different MTX assay methods on pharmacokinetic parameter calculations.
• To assess the accuracy of non-chromatographic assays compared to liquid chromatography for MTX analysis.

Main Methods:

• 13 children with acute lymphoblastic leukemia received MTX (5-8 g/m2) via 24-hour infusions.
• Plasma samples were analyzed using five methods: liquid chromatography (LC), enzyme inhibition assay (EIA), two fluorescence polarization immunoassays (FPIA1, FPIA2), and enzyme multiplied immunoassay (EMIT).
• Pharmacokinetic parameters (AUC, half-life) were compared between LC and non-chromatographic methods.

Main Results:

• Non-chromatographic methods (EIA, FPIA1, FPIA2, EMIT) showed significant variability compared to LC.
• Approximately 50% of pharmacokinetic parameters calculated from non-chromatographic assays deviated by more than 25% from LC-derived values.
• Terminal half-life and area under the concentration-time curve (AUC) were particularly affected.

Conclusions:

• The accuracy of MTX assay methods directly influences the reliability of pharmacokinetic data used for dose optimization.
• Non-chromatographic assays may compromise the precision of MTX therapeutic drug monitoring.
• Improvements in assay accuracy are needed to ensure optimal MTX therapy and patient outcomes in pediatric oncology.